Fallopian tube cancer
diseaseOn this page
Also known as cancer of fallopian tubecancer of fallopian tubesfallopian tube malignant neoplasmfallopian tube malignant tumorfallopian tube malignant tumourmalignant fallopian tube neoplasmmalignant fallopian tube tumormalignant fallopian tube tumourmalignant neoplasm of fallopian tubemalignant neoplasm of the fallopian tubemalignant neoplasm of uterine tubemalignant tubal tumormalignant tubal tumourmalignant tumor of fallopian tubemalignant tumor of fallopian tubesmalignant tumor of the fallopian tubemalignant tumour of fallopian tubesmalignant tumour of the fallopian tubeneoplasm, fallopian tube, malignant
Summary
Fallopian tube cancer (MONDO:0002158) is a cancer and 555 clinical trials. Top therapeutic interventions include paclitaxel, topotecan, and niraparib. A subtype of female reproductive organ cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Clinical trials: 555
Clinical features
Epidemiology
Prevalence records
4 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 1 | Europe | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.11 | United Kingdom | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.15 | Denmark | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.16 | United States | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | fallopian tube cancer |
| Mondo ID | MONDO:0002158 |
| Orphanet | 180242 |
| DOID | DOID:1964 |
| ICD-10-CM | C57.0 |
| ICD-11 | 459381514 |
| NCIT | C7480 |
| SNOMED CT | 363444001 |
| UMLS | C0153579 |
| MedGen | 102276 |
| GARD | 0020204 |
| MedDRA | 10025915 |
| Anatomy (UBERON) | UBERON:0003889 |
| Is cancer (heuristic) | yes |
Also known as: cancer of fallopian tube · cancer of fallopian tubes · fallopian tube cancer · fallopian tube malignant neoplasm · fallopian tube malignant tumor · fallopian tube malignant tumour · malignant fallopian tube neoplasm · malignant fallopian tube tumor · malignant fallopian tube tumour · malignant neoplasm of fallopian tube · malignant neoplasm of the fallopian tube · malignant neoplasm of uterine tube · malignant tubal tumor · malignant tubal tumour · malignant tumor of fallopian tube · malignant tumor of fallopian tubes · malignant tumor of the fallopian tube · malignant tumour of fallopian tubes · malignant tumour of the fallopian tube · neoplasm, fallopian tube, malignant (+4 more)
Data availability: 2 cell lines.
Disease family
This is a subtype of female reproductive organ cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › fallopian tube cancer
Related subtypes (8): vaginal cancer, vulva cancer, uterine cancer, adenocarcinofibroma, endometrioid adenocarcinoma, adenosarcoma, ovarian cancer, gestational choriocarcinoma
Subtypes (4): fallopian tube leiomyosarcoma, fallopian tube adenosarcoma, cancer of isthmus of fallopian tube, fallopian tube carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 555.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 197 |
| PHASE1 | 120 |
| Not specified | 93 |
| PHASE3 | 67 |
| PHASE1/PHASE2 | 56 |
| EARLY_PHASE1 | 16 |
| PHASE2/PHASE3 | 6 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01081262 | PHASE3 | ACTIVE_NOT_RECRUITING | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer |
| NCT01167712 | PHASE3 | ACTIVE_NOT_RECRUITING | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT02859038 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) |
| NCT03522246 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy |
| NCT04095364 | PHASE3 | ACTIVE_NOT_RECRUITING | Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT04515602 | PHASE3 | NOT_YET_RECRUITING | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) |
| NCT04575935 | PHASE3 | RECRUITING | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial |
| NCT05009082 | PHASE3 | RECRUITING | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer |
| NCT05281471 | PHASE3 | RECRUITING | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician’s Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) |
| NCT05445778 | PHASE3 | ACTIVE_NOT_RECRUITING | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer |
| NCT05659381 | PHASE3 | RECRUITING | Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
| NCT06751485 | PHASE3 | NOT_YET_RECRUITING | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer |
| NCT06824467 | PHASE3 | RECRUITING | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) |
| NCT06834672 | PHASE3 | RECRUITING | Study of IBI354 Versus Investigator’s Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT06915025 | PHASE3 | RECRUITING | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer |
| NCT06994195 | PHASE3 | RECRUITING | A Study Comparing BL-B01D1 With the Investigator’s Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) |
| NCT07472140 | PHASE2/PHASE3 | RECRUITING | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer |
| NCT07545460 | PHASE3 | NOT_YET_RECRUITING | A Study Comparing BL-M07D1 With Physician’s Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer |
| NCT00002895 | PHASE3 | COMPLETED | Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00003120 | PHASE3 | COMPLETED | S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission |
| NCT00003636 | PHASE3 | COMPLETED | Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer |
| NCT00004934 | PHASE3 | COMPLETED | Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer |
| NCT00006454 | PHASE3 | COMPLETED | Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer |
| NCT00028743 | PHASE3 | COMPLETED | Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00033605 | PHASE3 | COMPLETED | Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis |
| NCT00041080 | PHASE3 | COMPLETED | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| NCT00045461 | PHASE2/PHASE3 | UNKNOWN | Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer |
| NCT00052468 | PHASE3 | COMPLETED | Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer |
| NCT00075712 | PHASE2/PHASE3 | COMPLETED | Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
| NCT00098878 | PHASE3 | COMPLETED | Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| NCT00108745 | PHASE3 | UNKNOWN | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00189553 | PHASE3 | COMPLETED | Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse |
| NCT00226915 | PHASE3 | COMPLETED | Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma |
| NCT00245050 | PHASE3 | COMPLETED | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer |
| NCT00262847 | PHASE3 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
| NCT00262990 | PHASE3 | COMPLETED | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer |
| NCT00263822 | PHASE3 | COMPLETED | Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00382811 | PHASE3 | COMPLETED | OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer |
| NCT00483782 | PHASE3 | COMPLETED | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
| NCT00693342 | PHASE3 | WITHDRAWN | Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PACLITAXEL | 4 | 100 |
| TOPOTECAN | 4 | 26 |
| NIRAPARIB | 4 | 11 |
| MIRVETUXIMAB SORAVTANSINE | 4 | 10 |
| RUCAPARIB | 4 | 10 |
| CARBOPLATIN | 4 | 5 |
| OLAPARIB | 4 | 5 |
| DOXORUBICIN | 4 | 4 |
| ERLOTINIB HYDROCHLORIDE | 4 | 4 |
| PAZOPANIB | 4 | 3 |
| PYRIDOXINE | 4 | 3 |
| IFOSFAMIDE | 4 | 2 |
| IXABEPILONE | 4 | 2 |
| PEGFILGRASTIM | 4 | 2 |
| PEGINTERFERON ALFA-2B | 4 | 2 |
| ALVIMOPAN | 4 | 1 |
| AMIFOSTINE | 4 | 1 |
| APREPITANT | 4 | 1 |
| ATEZOLIZUMAB | 4 | 1 |
| BEVACIZUMAB | 4 | 1 |
| BICALUTAMIDE | 4 | 1 |
| CISPLATIN | 4 | 1 |
| EPIRUBICIN HYDROCHLORIDE | 4 | 1 |
| ERIBULIN MESYLATE | 4 | 1 |
| ERLOTINIB | 4 | 1 |
| ETOPOSIDE PHOSPHATE | 4 | 1 |
| FONDAPARINUX SODIUM | 4 | 1 |
| GANCICLOVIR | 4 | 1 |
| GEFITINIB | 4 | 1 |
| GOSERELIN | 4 | 1 |
Related Atlas pages
- Drugs: Paclitaxel, Topotecan, Niraparib, Mirvetuximab Soravtansine, Rucaparib, Carboplatin, Olaparib, Doxorubicin, Erlotinib, Pazopanib, Pyridoxine, Ifosfamide, Ixabepilone, Pegfilgrastim, PEGINTERFERON ALFA-2B, Alvimopan, Amifostine, Aprepitant, Atezolizumab, Bevacizumab, Bicalutamide, Cisplatin, Epirubicin, Eribulin, Etoposide Phosphate, Fondaparinux, Ganciclovir, Gefitinib, Goserelin